Breaking News Instant updates and real-time market news.

CELG

Celgene

$82.86

16.21 (24.32%)

, BMY

Bristol-Myers

$45.47

-6.55 (-12.59%)

12:23
01/03/19
01/03
12:23
01/03/19
12:23

Celgene downgraded to Market Perform from Outperform at Leerink

Leerink analyst Geoffrey Porges downgraded Celgene (CELG) to Market Perform from Outperform after the company agreed to be acquired by Bristol-Myers (BMY), stating that "the best deal is sometimes the only deal." He lowered his price target on Celgene shares to $102 from $112.

CELG

Celgene

$82.86

16.21 (24.32%)

BMY

Bristol-Myers

$45.47

-6.55 (-12.59%)

  • 03

    Jan

  • 03

    Jan

  • 03

    Jan

  • 06

    Jan

  • 24

    Jan

  • 28

    Jan

  • 18

    May

  • 20

    May

CELG Celgene
$82.86

16.21 (24.32%)

12/21/18
BTIG
12/21/18
INITIATION
BTIG
Neutral
Celgene assumed with a Neutral at BTIG
BTIG analyst Thomas Shrader last night assumed coverage of Celgene with a Neutral rating. Revlimid will face full generic competition in 2026 and possibly sooner, Shrader tells investors in a research note. He adds that while Celgene has been building a pipeline, he believes only luspatercept and Otezla have a high chance of blockbuster potential.
BMY Bristol-Myers
$45.47

-6.55 (-12.59%)

01/03/19
BARD
01/03/19
NO CHANGE
Target $92
BARD
Neutral
Baird calls Bristol-Myers buyout a 'very good deal' for Celgene
While admitting he was surprised as anyone to the news, Baird analyst Brian Skorney views the buyout by Bristol-Myers Squibb (BMY) as a "very good deal" for Celgene (CELG). The deal's success hinges on the outcome of Revlimid patent litigation, but for Celgene shareholders today, "its a big win," Skorney tells investors in a research note titled "Mega Mergers Are Back?" All told, the deal could be worth over $95 per share for Celgene, the analyst points out. With a contingent value right of $9.00 due in 2021, the analyst thinks the probability adjusted net present value of the CVR is around $5 to $6 per share. Skorney has a Neutral rating on Celgene with a $92 price target.
01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
01/03/19
PIPR
01/03/19
NO CHANGE
Target $23
PIPR
Overweight
Bristol acquisition of Celgene a positive for Fate, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes Bristol-Myers Squibb's (BMY) agreement to acquire Celgene (CELG) is in part driven by the long-term potential of cellular therapies to treat cancer. The analyst sees the deal announced this morning as a positive for Fate Therapeutics (FATE), which he notes is developing a pipeline of allogeneic and induced pluripotent stem cell natural killer and T-cell therapies. Fate is a potential acquisition target for its "rich cell therapy pipeline and platform," Tenthoff tells investors in a research note. Fate remains a top pick for Piper in 2019 and the analyst reiterates an Overweight rating on the shares with a $23 price target.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.

TODAY'S FREE FLY STORIES

NVDA

Nvidia

$209.88

1.33 (0.64%)

16:21
11/14/19
11/14
16:21
11/14/19
16:21
Hot Stocks
Nvidia CEO says gaming business and hyperscale demand powered Q3 results »

CEO Jensen Huang says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

UVE

Universal Insurance

$30.07

-0.43 (-1.41%)

16:21
11/14/19
11/14
16:21
11/14/19
16:21
Hot Stocks
Universal Insurance declares regular, special cash dividend »

Universal Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRE

Aprea Therapeutics

$26.92

2.45 (10.01%)

16:20
11/14/19
11/14
16:20
11/14/19
16:20
Earnings
Aprea Therapeutics reports Q3 EPS ($5.29), consensus ($3.94) »

As of September 30, prior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$209.88

1.33 (0.64%)

16:20
11/14/19
11/14
16:20
11/14/19
16:20
Earnings
Nvidia reports Q3 adjusted EPS $1.78, consensus $1.57 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/14/19
11/14
16:20
11/14/19
16:20
Options
Closing CBOE SPX and VIX Index summary for November 14th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$175.21

2 (1.15%)

16:19
11/14/19
11/14
16:19
11/14/19
16:19
Hot Stocks
Breaking Hot Stocks news story on RH »

RH up 7% in afterhours…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

$65.56

-0.14 (-0.21%)

16:19
11/14/19
11/14
16:19
11/14/19
16:19
Earnings
Dolby sees FY20 adjusted EPS $3.40-$3.50, consensus $2.87 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

CSSE

Chicken Soup for the Soul

$9.99

0.28 (2.88%)

16:19
11/14/19
11/14
16:19
11/14/19
16:19
Earnings
Chicken Soup for the Soul reports Q3 adjusted EPS ($1.03), consensus (5c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DLB

Dolby

$65.56

-0.14 (-0.21%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Earnings
Dolby sees Q1 adjusted EPS 45c-51c, consensus 65c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

CY

Cypress Semiconductor

$23.43

0.01 (0.04%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Downgrade
Cypress Semiconductor rating change  »

Cypress Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$91.26

-0.02 (-0.02%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Hot Stocks
Nike raises quarterly dividend to 24.5c from 22c per share »

The dividend declared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$109.21

4.195 (3.99%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Earnings
Globant raises FY19 non-IFRS EPS view to $2.23-$2.27 from $2.19-$2.25 »

Consensus $2.24. Narrows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSN

Celsion

$1.38

0.29 (26.73%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Celsion reports Q3 EPS (25c), consensus (28c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

HAYN

Haynes

$35.83

-0.31 (-0.86%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Haynes reports Q4 EPS 48c, consensus 40c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

DLB

Dolby

$65.56

-0.14 (-0.21%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Dolby reports Q4 adjusted EPS 66c, consensus 48c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

GLOB

Globant

$109.21

4.195 (3.99%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Globant sees Q4 non-IFRS adjusted EPS 58c-62c, consensus 63c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GIFI

Gulf Island Fabrication

$4.38

0.07 (1.62%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Hot Stocks
Gulf Island Fabrication board Chairman Jack Laborde to step down »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$109.21

4.195 (3.99%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Globant reports Q3 non-IFRS EPS 62c, consensus 59c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$175.21

2 (1.15%)

, BRK.A

Berkshire Hathaway

$329,095.00

-505 (-0.15%)

16:15
11/14/19
11/14
16:15
11/14/19
16:15
Hot Stocks
Warren Buffet's Berkshire Hathaway takes stake in RH »

The stake in RH was…

RH

RH

$175.21

2 (1.15%)

BRK.A

Berkshire Hathaway

$329,095.00

-505 (-0.15%)

BRK.B

Berkshire Hathaway

$219.42

-0.39 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
11/14/19
11/14
16:15
11/14/19
16:15
General news
Breaking General news story  »

Week of 11/4 Money Supply…

16:15
11/14/19
11/14
16:15
11/14/19
16:15
General news
Breaking General news story  »

Week of 11/13 Fed Balance…

HPQ

HP Inc.

$20.12

0.585 (2.99%)

, CLDR

Cloudera

$8.54

0.055 (0.65%)

16:14
11/14/19
11/14
16:14
11/14/19
16:14
Hot Stocks
Icahn bought 62.9M shares of HP, 54.8M shares of Cloudera in Q3 »

Carl Icahn disclosed in a…

HPQ

HP Inc.

$20.12

0.585 (2.99%)

CLDR

Cloudera

$8.54

0.055 (0.65%)

HTZ

Hertz

$16.27

-0.03 (-0.18%)

CZR

Caesars

$12.86

0.09 (0.70%)

CNDT

Conduent

$6.57

-0.07 (-1.06%)

IEP

Icahn Enterprises

$64.94

-0.1 (-0.15%)

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

LNG

Cheniere Energy

$61.18

-0.1 (-0.16%)

FCX

Freeport McMoRan

$10.81

-0.02 (-0.18%)

CVI

CVR Energy

$46.82

0.32 (0.69%)

HLF

Herbalife Nutrition

$43.57

-0.23 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

ZSAN

Zosano Pharma

$1.98

-0.04 (-1.98%)

16:13
11/14/19
11/14
16:13
11/14/19
16:13
Earnings
Zosano Pharma reports Q3 EPS (55c), consensus (58c) »

As of September 30, cash,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.